News
Glaucoma
treatment
option
launches
in Canada
VYZULTA, the first new treatment new innovative eye health medicines and periorbital tissue and growth of
option for glaucoma in nearly 20 that can help address current and eyelashes can occur.
years, is now available to health care emerging unmet medical needs and professionals in Canada, according to help create Moments that Matter for Bausch + Lomb. Canadians.” VYZULTA was approved by Health VYZULTA is a once daily monother- Ike Ahmed, assistant professor, Uni-
Canada on Dec. 27, 2018. apy with a dual mechanism of action, versity of Toronto; clinical professor,
which targets two pathways to reduce University of Utah; director, Glauco-
IOP. Following topical administra- ma & Advanced Anterior Segment
tion, VYZULTA is thought to lower Surgery (GAASS) Fellowship, Univer-
intraocular pressure by increasing sity of Toronto; and research director,
outflow of aqueous humor through Kensington Eye Institute, University
both uveoscleral and trabecular of Toronto. “It is a unique molecule
Indicated for the reduction of intraocu-
lar pressure in patients with open-angle
glaucoma or ocular hypertension,
VYZULTA is also the first modified
prostaglandin analog with one of its
metabolites being Nitric Oxide.
“VYZULTA represents an evolution
in topical monotherapy in Canada in
the treatment of glaucoma,” says Dr.
meshwork routes. The innovative that targets two outflow pathways to
“We’re excited that VYZULTA is now treatment is rapidly metabolized improve IOP reduction. I am pleased
available as a treatment option for in the eye to latanoprost acid (main to see that a recognized eye care com-
people who suffer from glaucoma in active metabolite), an F2a prostaglan- pany like Bausch + Lomb is investing
Canada – the second global market din analogue, and likely butanediol in innovative research to advance the
to offer this new advancement,” said mononitrate. The most common treatment of glaucoma, and ultimate-
Richard Lajoie, president and general ocular adverse events include con- ly to help eye care providers and their
manager, Bausch Health, Canada. junctival hyperemia, eye irritation, patients to preserve sight.” OP
“Bausch + Lomb remains committed to eye pain and instillation site pain. improving people’s lives by developing Increased pigmentation of the iris
38 Optical Prism | March 2020